🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Miriam Freimer

The Ohio State University Wexner Medical Center

ORCID: 0000-0001-8282-764X

Also affiliated with The Ohio State University

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 4%percentile
0.879Author DataRank

Indexed papers

2in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Epidemiological evidence for a hereditary contribution to myasthenia gravis: a retrospective cohort study of patients from North America

BMJ Open(2020)10.1136/bmjopen-2020-037909
Top 23%
0.879DataRank
Top 23%20 citations

Richard J. Barohn, Emanuela Bartoccion, Michael Benatar, Derrick Blackmore, Vinay Chaudhry +35 more

Papers

Driven by 14 papers — median percentile 77. Top paper: “Randomized Double-Blind Placebo-Controlled Trial of the Corticosteroid-Sparing Effects of Immunoglobulin in Myasthenia Gravis”.

Randomized Double-Blind Placebo-Controlled Trial of the Corticosteroid-Sparing Effects of Immunoglobulin in Myasthenia Gravis

Neurology(2022)10.1212/wnl.0000000000201501
N/A
1.2DataRank · unranked
25 citations

Andrzej Szczudlik, Antanas Vaitkus, Csilla Rózsa, Anna Kostera‐Pruszczyk, Petr Hon +20 more

Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study

Therapeutic Advances in Neurological Disorders(2024)10.1177/17562864241243186
N/A
0.992DataRank · unranked
38 citations

Saskia Bresch, Constantine Farmakidis, Miriam Freimer, Angela Genge, Channa Hewamadduma +23 more

Epidemiological evidence for a hereditary contribution to myasthenia gravis: a retrospective cohort study of patients from North America

BMJ Open(2020)10.1136/bmjopen-2020-037909
Top 23%
0.879DataRank
Top 23%20 citations

Richard J. Barohn, Emanuela Bartoccion, Michael Benatar, Derrick Blackmore, Vinay Chaudhry +35 more

Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trial

The Lancet Neurology(2023)10.1016/s1474-4422(23)00275-2
N/A
0.867DataRank · unranked
34 citations

Michael McDermott, Thomas Blaettler, Claus Sundgreen, Anthony A. Amato, Emma Ciafaloni +74 more

104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07)

Journal of Neurology(2024)10.1007/s00415-024-12236-0
N/A
0.803DataRank · unranked
28 citations

Priya S. Kishnani, Drago Bratkovic, Barry J. Byrne, Kristl G. Claeys, Jordi Díaz‐Manera +79 more

Age- and Sex-Related Differences in Patients With Wild-Type Transthyretin Amyloidosis

JACC: Advances(2024)10.1016/j.jacadv.2024.101086
N/A
0.425DataRank · unranked
16 citations

Angela Dispenzieri, Arnt V. Kristen, Mathew S. Maurer, Igor Diemberger, Brian M. Drachman +51 more

Switching to subcutaneous zilucoplan from intravenous complement component 5 inhibitors in generalised myasthenia gravis: a phase IIIb, open-label study

Therapeutic Advances in Neurological Disorders(2025)10.1177/17562864251347283
N/A
0.344DataRank · unranked
6 citations

Urvi Desai, Raghav Govindarajan, Min Kyun Kang, Shaida Khan, Bhupendra Khatri +11 more

Zilucoplan in immune-mediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trial

The Lancet Rheumatology(2023)10.1016/s2665-9913(23)00003-6
N/A
0DataRank · unranked
55 citations

Anthony A. Amato, Mazen M. Dimachkie, Hector Chinoy, Yessar Hussain, James B Lilleker +43 more

Multidisciplinary amyloidosis care in the era of personalized medicine

Frontiers in Neurology(2022)10.3389/fneur.2022.935936
N/A
0DataRank · unranked
14 citations

Rami Kahwash, Samir V. Parikh, Michael Isfort, Miriam Freimer, Ajay Vallakati +6 more

Provisional practice recommendation for the management of myopathy in VCP‐associated multisystem proteinopathy

Annals of Clinical and Translational Neurology(2023)10.1002/acn3.51760
N/A
0DataRank · unranked
9 citations

Allison Peck, Teresinha Evangelista, Gerald Pfeffer, Leo Wang, Jordi Díaz‐Manera +15 more

Development of a standard of care for patients with valosin-containing protein associated multisystem proteinopathy

Orphanet Journal of Rare Diseases(2022)10.1186/s13023-022-02172-5
N/A
0DataRank · unranked
36 citations

Allison Peck, Lindsay N. Alfano, Kenneth I. Berger, M. James, Nupur Ghoshal +50 more

Identification of genetic risk loci and prioritization of genes and pathways for myasthenia gravis: a genome-wide association study

Proceedings of the National Academy of Sciences(2022)10.1073/pnas.2108672119
N/A
0DataRank · unranked
133 citations

Sara Sáez-Atiénzar, Natalie A. Murphy, Adriano Chiò, Cornelis Blauwendraat, Ricardo H. Roda +48 more

Beta-Adrenergic Antagonist Tolerance in Amyloid Cardiomyopathy

Frontiers in Cardiovascular Medicine(2022)10.3389/fcvm.2022.907597
N/A
0DataRank · unranked
7 citations

Carlos Bermúdez, Cyril Ayuk Mbeng Takem Baiyee, Brandon Rodgers, Samir M. Parikh, Salem Almaani +10 more

A Genome-Wide Association Study of Myasthenia Gravis

UNC Libraries(2020)10.17615/hk4s-3m41
N/A
0DataRank · unranked
0 citations

Emanuela Bartoccioni, Michael A. Nalls, Mamatha Pasnoor, Mario Sabatelli, April McVey +27 more